Cited by 118Inhalation and Respiratory Drug DeliveryNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

The DOI matches its Crossref record.

Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review

Gill, Simardeep, Löbenberg, Raimar, Ku, Tabitha, Azarmi, Shirzad, Roa, Wilson, Prenner, Elmar J.·2007·Journal of Biomedical Nanotechnology

DOI 10.1166/jbn.2007.015

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1166/jbn.2007.015

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Inhaled nanoparticles—A current review
Yang, W. P., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 697
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
“The use of neutral NPs as drug delivery vehicles is the most common approach in anti-TB therapy.(206) Ciprofloxacin encapsulated in liposomes has been employed in anti-TB therapy, offering pulmonary delivery through nebulization.”
Method
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
Self-citation
Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates
Abdelaziz, H. M., Gaber, M. K., Elwakil, M. M. A., Mabrouk, M. T., Elgohary, M. M., Kamel, N. M., Kabary, D. M., Freag, M. S., Samaha, M. W., Mortada, S. M., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.036 · Cited by 417
Drug nanocrystals: in vivo performances.
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., & Li, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.013 · Cited by 347
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264
Formation, characterization, and fate of inhaled drug nanoparticles
Zhang, J., Wu, L., Chan, H., & Watanabe, W. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.002 · Cited by 213
Soybeans as a Phytochemical Reservoir for the Production and Stabilization of Biocompatible Gold Nanoparticles
Shukla, R., Nune, S. K., Chanda, N., Katti, K. K., Mekapothula, S., Kulkarni, R. R., Welshons, W. V., Kannan, R., & Katti, K. V. (2008) · Small · doi:10.1002/smll.200800525 · Cited by 204
Controlled pulmonary drug and gene delivery using polymeric nano-carriers
Beck-Broichsitter, M., Merkel, O. M., & Kissel, T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.004 · Cited by 200
Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model
Roa, W., Azarmi, S., Alhallak, K., Finlay, W. H., Magliocco, A. M., & Löbenberg, R. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.035 · Cited by 181
Self-citation
Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives
Poh, T. Y., Ali, N. A. B. M., Aogáin, M. M., Kathawala, M. H., Setyawati, M. I., Ng, K. W., & Chotirmall, S. H. (2018) · Particle and Fibre Toxicology · doi:10.1186/s12989-018-0282-0 · Cited by 176
Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines
Guo, Y., Bera, H., Shi, C., Zhang, L., Cun, D., & Yang, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.015 · Cited by 172
Nanoparticulate drug delivery systems for cancer chemotherapy
Saha, R. N., Sekar, V., Bende, G., & Snehalatha, M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.510804 · Cited by 163
“It is expected that within 10 years, 50% of all drug delivery and design approaches may be shifted to Nanoparticulate Drug Delivery Systems (NPDDS) technology (Gill et al. 2007).”
BackgroundInfluential
A database for deliquescence and efflorescence relative humidities of compounds with atmospheric relevance
Peng, C., Chen, L., & Tang, M. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.11.021 · Cited by 164
Nano-QSAR modeling for predicting biological activity of diverse nanomaterials
Singh, K. P., & Gupta, S. (2014) · RSC Advances · doi:10.1039/c4ra01274g · Cited by 154
Translational nanomedicine: status assessment and opportunities
Murday, J. S., Siegel, R. W., Stein, J. A., & Wright, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.06.001 · Cited by 153
Spray freeze drying for dry powder inhalation of nanoparticles
Ali, M. E., & Lamprecht, A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.009 · Cited by 143
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections
Günday-Türeli, N., Torge, A., Juntke, J., Schwarz, B., Schneider‐Daum, N., Türeli, A. E., Lehr, C., & Schneider, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.032 · Cited by 133
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123
Micro- and nanocarrier-mediated lung targeting
Kurmi, B. D., Kayat, J., Gajbhiye, V., Tekade, R. K., & Jain, N. K. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.492212 · Cited by 122
“Drug delivery to lungs is an attractive horizon owing to the large surface area of the alveolar region, lower thickness of the epithelial barrier, extensive vascularization, relatively low proteolytic activity in the alveolar space as compared with other routes of administration and absence of the first-pass metabolis…”
Background
Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery
Huang, Y., Li, R., Chen, J.-Y., & Chen, J. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.11.072 · Cited by 123
“The proposed mechnism of NP deposition is Brownian diffusion, which occurs in the cinar region of the lungs (Gill et al., 2007).”
Background
Respirable nanocarriers as a promising strategy for antitubercular drug delivery
Mehanna, M. M., Mohyeldin, S. M., & Elgindy, N. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.038 · Cited by 119
Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro
Beck‐Broichsitter, M., Ruppert, C., Schmehl, T., Guenther, A., Betz, T., Bakowsky, U., Seeger, W., Kissel, T., & Gessler, T. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.10.007 · Cited by 116
Liposomes as Drug Delivery Systems for The Treatment of TB
Pinheiro, M., Lúcio, M., Lima, J. L. F. C., & Reis, S. (2011) · Nanomedicine · doi:10.2217/nnm.11.122 · Cited by 114
Recent applications and strategies in nanotechnology for lung diseases
Zhong, W., Zhang, X., Zeng, Y., Lin, D., & Wu, J. (2021) · Nano Research · doi:10.1007/s12274-020-3180-3 · Cited by 116
Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery
Varshosaz, J., Ghaffari, S., Mirshojaei, S. F., Jafarian‐Dehkordi, A., Atyabi, F., Kobarfard, F., & Azarmi, S. (2013) · BioMed Research International · doi:10.1155/2013/136859 · Cited by 110
“As Zetasizer and SEM pictures confirmed the optimized SLNs had suitable size (<200 nm) and zeta potential (+7mV) to escape from being uptaken by the alveolar macrophages [5, 6, 12].”
BackgroundSelf-citation
Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer
Meenach, S. A., Anderson, K. W., Hilt, J. Z., McGarry, R. C., & Mansour, H. M. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.05.012 · Cited by 115
Inhaled nanoparticles–An updated review
Praphawatvet, T., Peters, J. I., & Williams, R. O. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119671 · Cited by 105
Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: In vitro and in vivo studies
Jyoti, K., Kaur, K., Pandey, R. S., Jain, U. K., Chandra, R., & Madan, J. (2015) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2014.12.092 · Cited by 85
Advances in Device and Formulation Technologies for Pulmonary Drug Delivery
Chan, J. G. Y., Wong, J., Zhou, Q. T., Leung, S. S. Y., & Chan, H. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0114-y · Cited by 82
“ability, chemical composition, particle size, and local concentration (123, 124).”
Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols
Mansour, H. M., Meenach, S. A., Vogt, McGarry, Anderson, �., & Hilt, J. Z. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s30724 · Cited by 77
“Synthetic DPPC (molecular weight 734.039 g/mol, .”
Influential
Synthesis and in vitro study of cisplatin-loaded Fe 3 O 4 nanoparticles modified with PLGA-PEG 6000 copolymers in treatment of lung cancer
Nejati‐Koshki, K., Abbasi, M. M., Ebrahimi, E., et al. (2014) · Journal of Microencapsulation · doi:10.3109/02652048.2014.940011 · Cited by 76
“, 2007) including second-hand smoke (Gill et al., 2007; Roy et al., 2011).”
Background
Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles
Beck‐Broichsitter, M., Ruppert, C., Schmehl, T., Günther, A., & Seeger, W. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.10.016 · Cited by 65
Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review
Sabir, F., Qindeel, M., Zeeshan, M., Ain, Q. U., Rahdar, A., Barani, M., González, E., & Aboudzadeh, M. A. (2021) · Processes · doi:10.3390/pr9040621 · Cited by 56
“Nanoparticles produce pulmonary toxicity by oxidative stress because of the production of reactive oxygen species within the biological system [137].”
Background
Pulmonary drug delivery applications of natural polysaccharide polymer derived nano/micro-carrier systems: A review
Balde, A., Kim, S., Benjakul, S., & Nazeer, R. A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.116 · Cited by 52
Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach
Günday-Türeli, N., Türeli, A. E., & Schneider, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.025 · Cited by 50
Mechanisms of toxicity induced by SiO2 nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins A mRNA expression and nanoparticles uptake
Farcal, L. R., Uboldi, C., Méhn, D., Giudetti, G., Nativo, P., Ponti, J., Gilliland, D. D., Rossi, F., & Bal‐Price, A. (2012) · Nanotoxicology · doi:10.3109/17435390.2012.710658 · Cited by 48
“strated that the unique physiochemical properties of nanoparticles are attributed to their small size, large surface area, chemical composition, surface reactivity, charge, shape and interactions with different kinds of proteins (Oberdorster et al. 2005; Gill et al. 2007).”
Background
Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy?
Alhallak, K., Azarmi, S., Anwar‐Mohamed, A., Roa, W., & Löbenberg, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.05.002 · Cited by 45
“The lungs, as a part of the MPS, are extensively rich in alveolar macrophages [10].”
BackgroundSelf-citation
Controllable preparation and formation mechanism of BSA microparticles using supercritical assisted atomization with an enhanced mixer
Wang, Q., Guan, Y., Yao, S., & Zhu, Z. (2010) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2010.12.002 · Cited by 45
Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments
Gupta, C., Jaipuria, A., & Gupta, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010139 · Cited by 44
“One major risk involved is pulmonary toxicity due to the high concentration of drugs in the lungs [14].”
Background
Skin targeting by chitosan/hyaluronate hybrid nanoparticles for the management of irritant contact dermatitis: In vivo therapeutic efficiency in mouse-ear dermatitis model
Abuelella, K. E., Abd-Allah, H., Soliman, S. M., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123458 · Cited by 43
Formulating protein therapeutics into particulate forms
Yang, S., Yuan, W., & Jin, T. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903156374 · Cited by 43
“To ensure that therapeutics reach pulmonary alveoli (which represent sufficient area of mucosa), protein-loading particles have to be formulated in the range of 1 – 5 μm in diameter so that they can be carried in by the airflow of respiration to the destination without earlier deposition and exhalation [3,4].”
Background
Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation
Gulin-Sarfraz, T., Jonasson, S., Wigenstam, E., von Haartman, E., Bucht, A., & Rosenholm, J. M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040149 · Cited by 41
“Drug-loaded particles, compared to free drugs, also have a higher ability to reach the lower parts of the lungs [26,27].”
Background
Pulmonary delivery of anti-inflammatory agents
Ali, M. E., McConville, J. T., & Lamprecht, A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993968 · Cited by 39
“Pulmonary drug delivery has many advantages over other routes of drug administration and drug absorption, including the large alveolar surface area, extensive vascularization (about 5 l/min), low thickness of the epithelial barrier and the limited enzymatic activity compared to other routes of administration [7-9].”
Background
Pulmonary Toxicity of Polysorbate-80-coated Inhalable Nanoparticles; In vitro and In vivo Evaluation
Alhallak, K., Azarmi, S., Sun, C., Lai, P. K., Prenner, E. J., Roa, W., & Löbenberg, R. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9190-4 · Cited by 37
Self-citation
Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models
Beck‐Broichsitter, M., Schmehl, T., Seeger, W., & Gessler, T. (2010) · Journal of Nanomaterials · doi:10.1155/2011/163791 · Cited by 39
“However, the relevance of these findings for the in vivo translocation of inhaled ultrafine particles remains to be established, owing to the fact that polymeric nanoparticles are currently under investigation as potential drug delivery systems to the lung [95].”
Background
Release, Characterization, and Safety of Nanoencapsulated Food Ingredients
Jafari, S. M., Esfanjani, A. F., Katouzian, I., & Assadpour, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809740-3.00010-6 · Cited by 53
Targeted delivery of anti-tuberculosis drugs to macrophages: targeting mannose receptors
Filatova, L. Y., Klyachko, N. L., & Kudryashova, E. V. (2018) · Russian Chemical Reviews · doi:10.1070/rcr4740 · Cited by 35
Current advances in drug delivery of nanoparticles for respiratory disease treatment
de Menezes, B. R. C., Rodrigues, K. F., Schatkoski, V. M., Pereira, R. M., Ribas, R. G., Montanheiro, T. L. D. A., & Thim, G. P. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01783c · Cited by 34
Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion
Ebrahimi, S., Shamloo, A., Alishiri, M., Mofrad, Y. M., & Akherati, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121133 · Cited by 34
Nanogold-Gallate Chitosan-Targeted Pulmonary Delivery for Treatment of Lung Cancer
Komenek, S., Luesakul, U., Ekgasit, S., et al. (2016) · AAPS PharmSciTech · doi:10.1208/s12249-016-0644-6 · Cited by 34
Deposition of Inhaled Ultrafine Aerosols in Replicas of Nasal Airways of Infants
Golshahi, L., Finlay, W. H., Olfert, J. S. S., et al. (2010) · Aerosol Science and Technology · doi:10.1080/02786826.2010.488256 · Cited by 31
“Nanomedicine, including the use of nanoparticles, has potential for the therapeutic treatment of diseases via manipulation of particle characteristics such as size, surface chemistry, surface charge, and surface area (Gill et al. 2007).”
Polymeric Nanoparticles for Inhaled Vaccines
Al‐Nemrawi, N. K., Darweesh, R. S., Alshriem, L. A., Al-Qawasmi, F. S., Emran, S. O., Khafajah, A. S., & Abu‐Dalo, M. (2022) · Polymers · doi:10.3390/polym14204450 · Cited by 30
Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics
Obeng, E. M., Dzuvor, C. K. O., & Danquah, M. K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101350 · Cited by 27
Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment
Bekraki, A. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00007-2 · Cited by 28
Aptamers as promising nanotheranostic tools in the COVID ‐19 pandemic era
Dzuvor, C. K. O., Tettey, E. L., & Danquah, M. K. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1785 · Cited by 24
“In addition, these platforms possess superb bioavailability, longer blood circulatory properties, and pharmacokinetics profile (Gill et al., 2007; Li et al., 2018), which makes them perfect for curbing lung-related or respiratory diseases of which COVID-19 is no exception.”
Background
Nontoxic impact of PEG-coated gold nanospheres on functional pulmonary surfactant-secreting alveolar type II cells
Bouzas, V., Haller, T., Hobi, N., Felder, E., Pastoriza‐Santos, I., & Pérez‐Gil, J. (2013) · Nanotoxicology · doi:10.3109/17435390.2013.829878 · Cited by 25
“The size of NPs is the critical parameter that defines the site of deposition within the respiratory tract (Gill et al. 2007).”
Background
Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)
Yadav, K. S., Upadhya, A., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1832989 · Cited by 24
State of the Art of Nanobiotechnology Applications in Neglected Diseases
Durán, N., Marcato, P. D., Teixeira, Z., Durán, M., Costa, F. T. M., & Brocchi, M. (2009) · Current Nanoscience · doi:10.2174/157341309789378069 · Cited by 23
“Nanotechnology in the field of pharmaceutical biotechnology has had a positive influence on medical and pharmaceutical sciences [1-7].”
Background
Biogenic Nano-Synthesis; towards the Efficient Production of the Biocompatible Gold Nanoparticles
Gajanan, G., Eom, C., Kim, S. W., et al. (2010) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2010.31.10.2771 · Cited by 23
DRUG-RESISTANT TUBERCULOSIS: RECENT APPROACH IN POLYMER BASED NANOMEDICINE
Shaji, J., & Shaikh, M. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2016v8i10.11295 · Cited by 21
“Moreover, the NPs can be engineered by attaching different ligands for active targeting of an area of interest like alveolar macrophages (AMs) [43].”
Background
Improved camptothecin encapsulation and efficacy by environmentally sensitive block copolymer/chitosan/fucoidan nanoparticles for targeting lung cancer cells
Don, T., Hong, Y., Jheng, P., Chuang, E., & Huang, Y.-C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133901 · Cited by 21
Relevance of Two-Dimensional Brownian Motion Dynamics in Applying Nanoparticle Tracking Analysis
der Meeren, P. V., Kasinos, M., & Saveyn, H. G. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-953-2_42 · Cited by 21
Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200523174108 · Cited by 21
High-voltage, electric field-driven micro/nanofabrication for polymeric drug delivery systems
Xie, Y., & Castracane, J. (2009) · IEEE Engineering in Medicine and Biology Magazine · doi:10.1109/memb.2008.931013 · Cited by 20
Core–shell drug carriers: liposomes, polymersomes, and niosomes
Dan, N. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00002-6 · Cited by 21
Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases
Ali, R., Mittal, G., Ali, R., et al. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2013.764937 · Cited by 18
“…Carvalho et al., 2011), local action, low enzyme activity, immediate therapeutic concentration at low dose, high safety index and increased patient compliance due to non-invasive nature (Gill et al., 2007; Mansour et al., 2009) makes it a preferred route for treating various respiratory disorders.”
Background
Ecotoxicity studies of two atrazine nanoformulations: From the evaluation of stability in media to the effects on aquatic organisms
Castanha, R. F., Pereira, A. D. E. S., Villarreal, G. P. U., et al. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122235 · Cited by 17
Harnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering
Obeng, E. M., Fulcher, A. J., & Wagstaff, K. M. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108108 · Cited by 21
Experimental sensing and density functional theory study of an ionic liquid mediated carbon nanotube modified carbon-paste electrode for electrochemical detection of metronidazole
Saghravanian, M., Ebrahimi, M., Es’haghi, Z., et al. (2017) · South African Journal of Chemistry · doi:10.17159/0379-4350/2017/v70a5 · Cited by 17
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 16
In Vitro Investigation of Influences of Chitosan Nanoparticles on Fluorescein Permeation into Alveolar Macrophages
CHACHULI, S. H. M., Nawaz, A., Shah, K. U., et al. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1893-5 · Cited by 14
Reducing the cytotoxicity of magnesium oxide nanoparticles using cerium oxide shell coating: An in vitro and in vivo study
Soltani, M., Karami‐Mohajeri, S., Ranjbar, M., Ahmadi, N., Jafari, E., Mandegari, A., & Heydari, M. R. (2023) · Ceramics International · doi:10.1016/j.ceramint.2023.01.069 · Cited by 14
Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Günday-Türeli, N., Türeli, A. E., & Schneider, M. (2014) · Drug Delivery Letters · doi:10.2174/2210303104666140222002101 · Cited by 12
Vesicle-based drug carriers
Dan, N. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813627-0.00001-6 · Cited by 14
Radiation Protection with Nanoparticles
Baker, C. H. (2011) · Science Publishers eBooks · doi:10.1201/b11076-15 · Cited by 12
Highly efficient pulmonary delivery of levo-tetrahydropalmatine using γ-cyclodextrin metal-organic framework as a drug delivery platform
Nie, Q., Wang, C., Xu, H., Mittal, P., Naeem, A., Zhou, P., Li, H., Zhang, Y., Guo, T., Sun, L., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104296 · Cited by 13
RECENT MODALITIES IN DRUG DELIVERY VIA INHALATION THERAPY – AN ADVANCED TREATMENT STRATEGY FOR PULMONARY CARCINOMA
Rajendran, R., Rajan, B., Ganesan, N., & Devaki, T. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 10
Nanocarrier-Assisted Antimicrobial Therapy Against Intracellular Pathogens
Kumar, L., Verma, S., Vaidya, B., & Mehra, N. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46152-8.00013-5 · Cited by 11
Targeted Delivery of Surface-Modified Nanoparticles: Modulation of Inflammation for Acute Lung Injury
Nguyen, H. X. (2019) · Springer eBooks · doi:10.1007/978-3-030-06115-9_17 · Cited by 11
Characterization and performance evaluation of pH-sensitive drug delivery of mesoporous silica with honeycomb structure for treatment of cancer
Duan, L., Shirazian, S., & Zare, M. H. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124680 · Cited by 12
Hygroscopicity and the water-polymer interaction parameter of nano-sized biodegradable hydrophilic substances
Mao, C.-N., Malek, K. A., & Asa-Awuku, A. (2021) · Aerosol Science and Technology · doi:10.1080/02786826.2021.1931012 · Cited by 9
“Additionally, organic nano-particles are intentionally produced and inhaled for aerosol therapy (Muralidharan et al. 2015; Azarmi, Roa, and L€obenberg 2008; Gill et al. 2007; Agnihotri, Mallikarjuna, and Aminabhavi 2004; Malcolmson and Embleton 1998).”
Background
Polycaprolactone Nanoparticles Boost Licofelone Transdermal Delivery for Osteoarthritis: In Vitro Characterization, Ex Vivo Permeability, and In Vivo Efficacy
Abuelella, K. E., Mosallam, S., El-Gazar, A. A., et al. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10240-z · Cited by 7
Biophysical analysis of gelatin and PLGA nanoparticle interactions with complex biomimetic lung surfactant models
Daear, W., Sule, K., Lai, P. K., & Prenner, E. J. (2022) · RSC Advances · doi:10.1039/d2ra02859j · Cited by 8
Self-citation
Dielectric Properties Tangential to the Interface in Model Insoluble Monolayers: Theoretical Assessment
Shushkov, P., Tzvetanov, S., Ivanova, A., et al. (2008) · Langmuir · doi:10.1021/la703616c · Cited by 7
Nanocrystals based mucosal delivery system: research advances
Liu, Y., Shuai, S., Huang, G. S., Chen, Y., Shen, B., & Yue, P. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2053985 · Cited by 6
TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells
Kan, S., Grainge, C., Nichol, K., Reid, A. T., Knight, D. A., Sun, Y. J., Bartlett, N. W., & Liang, M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121586 · Cited by 7
Nanoparticle Functionalization for Brain Targeting Drug Delivery and Diagnostic
Gomes, M. J., Mendes, B. B., Martins, S., & Sarmento, B. F. C. C. (2015) · Springer eBooks · doi:10.1007/978-3-319-15338-4_42 · Cited by 6
Engineering porous vaterite CaCO₃ nanostructures via alcohol–surfactant coordination in co-precipitation: A facile route to tunable drug-carrier platforms
Kim, S.-Y., Kim, S.-Y., Kang, M.-K., et al. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115592 · Cited by 4
Inhalable Polymeric Micro and Nano-immunoadjuvants for Developing Therapeutic Vaccines in the Treatment of Non-small Cell Lung Cancer
Dondulkar, A., Akojwar, N., Katta, C. B., Khatri, D. K., Mehra, N. K., Singh, S. B., & Madan, J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211104155604 · Cited by 4
Pulmonary Drug Delivery with Nanoparticles
Beck‐Broichsitter, M., Schmehl, T., Seeger, W., & Gessler, T. (2011) · Science Publishers eBooks · doi:10.1201/b11076-13 · Cited by 4
Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery
Dakkah, A. N., Bataineh, Y. A., Al-Jaidi, B. A., Bayan, M. F., & Nimer, N. A. (2020) · Engineering materials · doi:10.1007/978-3-030-36260-7_13 · Cited by 3
Development and Characterization of Nanocarrier Systems for the Delivery of Antitubercular Drugs
Ribeiro, R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/b6v3-t472 · Cited by 3
Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers
Arca, S., Witjaksono, C., Pons, F., & Lebeau, L. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107222 · Cited by 4
Improvement in the bioavailability of poorly water-soluble drugs via pulmonary delivery of nanoparticles
Yang, W. P. (2009) · Texas ScholarWorks (Texas Digital Library) · Cited by 2
Applications of pulsed laser ablation for enhanced gold nanofluids
Hur, T.-B., Phuoc, T. X., Chyu, M. K., et al. (2012) · Journal of Applied Physics · doi:10.1063/1.4752876 · Cited by 2
Nanoparticles
Rasulev, B., Leszczyńska, D., & Leszczyński, J. (2011) · IGI Global eBooks · doi:10.4018/978-1-60960-860-6.ch003 · Cited by 2
“…experiments are published in the last few years (Choi et al, 2008; Lewinski et al, 2008; Franklin et al, 2007; Duffin et al, 2007; Fiorito, 2007; Gill et al, 2007;Powers et al, 2007; Medina et al, 2007; Moore, 2006; Karakoti et al, 2006; Moss & Wong, 2006; Lee & Cho, 2006; Tsuji et al, 2006;…”
Background
Toxicological Aspects of Polymer Nanoparticles
Irache, J. M., Martín‐Arbella, N., Ojer, P., Azqueta, A., & de Ceráin, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-41421-8_16 · Cited by 4
Nanopharmaceuticals
Yurdasiper, A., Arıcı, M., & Özyazıcı, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-40016-9.00007-5 · Cited by 2
Asymmetric particles for pulmonary drug delivery
Köhler, D. (2010) · Max Planck Institute for Plasma Physics · doi:10.22028/d291-22691 · Cited by 2
“1μm in the alveoli) make the lung an interesting drug delivery route due to the high drug absorption and the ability to circumvent the first pass effect [7, 8].”
Background

Authors: Gill, S., Löbenberg, R., Ku, T., Azarmi, S., Roa, W., & Prenner, E. J.
ORCID: Löbenberg, Raimar
Roa, Wilson
Prenner, Elmar J.
Venue: Journal of Biomedical Nanotechnology
Publisher: American Scientific Publishers
Published: 2007-06-01
Volume: 3
Issue: 2
Pages: 107-119
ISSN: 1550-7033 (ISSN-L)
0000-0000
DOI: 10.1166/jbn.2007.015
OpenAlex: W2329541536
Cited by: 118
References: 0
Citations by year: 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 7
FWCI: 6.60
Type: journal article
Language: en
Open access: closed
Locations: Journal of Biomedical Nanotechnology (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: nanoparticles, pulmonary drug delivery, mechanism of action, nanoparticle toxicity, aerosolized nanoparticles, lung deposition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks